Physician profile
Amy K Studer
NPI 1215443171
$3,045.29
in general payments reported to CMS, 2019-2025
21 companies · $825 in 2025
The $825 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $358 · 2022: $351 · 2023: $798 · 2024: $714 · 2025: $825.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,336.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $901.75 | 2021-2025 | |
| Novo Nordisk INC | $432.13 | 2021-2024 | Rybelsus, Ozempic |
| Lilly USA, LLC | $375.43 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $200.37 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $157.41 | 2022-2025 | Airsupra, Breztri |
| Paratek Pharmaceuticals, INC. | $147.09 | 2024-2025 | Nuzyra, Xhance |
| Inspire Medical Systems, INC. | $127.12 | 2025 | Inspire |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $114.41 | 2025 | Caplyta |
| Pfizer INC. | $112.92 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.07 | 2024 | Jardiance |
| Exact Sciences Corporation | $102.76 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Myriad Women'S Health, INC. | $45.04 | 2023 | Myrisk |
| Astellas Pharma US INC | $42.23 | 2023-2024 | Veozah |
| Dexcom, INC. | $39.25 | 2023-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $36.54 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $22.87 | 2025 | Nexplanon |
| Abbott Laboratories | $18.89 | 2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $15.77 | 2021 | |
| Si-Bone, INC. | $15.23 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $14.53 | 2021 | |
| Philips North America LLC | $12.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Studer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.